Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E.K. Waller

Global Pivotal Phase 2 Trial of the Cd19-Targeted Therapy Ctl019 in Adult Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)-An Interim Analysis

Hematological Oncology

English

Impact of Post-Transplant Lymphoproliferative Disorder Subtype on Survival

Hematological Oncology

English

Related publications

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology

English

A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology

English

Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)

Hematological Oncology

English

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Hematological Oncology

English

Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes

Hematological Oncology

English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

English

Intravenous Immunoglobulin Therapy Use in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Juliet Trial

Hematological Oncology

English

Pcn72 - Budget Impact Analysis of Tisagenlecleucel for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in England

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E.K. Waller

Global Pivotal Phase 2 Trial of the Cd19-Targeted Therapy Ctl019 in Adult Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)-An Interim Analysis

Impact of Post-Transplant Lymphoproliferative Disorder Subtype on Survival

Related publications

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Intravenous Immunoglobulin Therapy Use in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Juliet Trial

Pcn72 - Budget Impact Analysis of Tisagenlecleucel for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in England